Date: Nov 14, 2014 This WuXi AppTec event is complementary and open to life science professionals globally. Nearly 500 life science innovators tuned in to our global webinar on November 14th to gain insights into the unique challenges and opportunities in rare disease R&D. We brought together our industry’s foremost experts from Third Rock Ventures, Shire, Editas Medicine, and Genzyme to discuss the newest R&D advancements in disease understanding, diagnosis, and therapeutic intervention. The panel faculty also shared perspectives on patient engagement, clinical and regulatory pathways, pricing, and market accessibility to orphan drugs. During the interactive discussion, the panel addressed many of the over 40 questions submitted by audience in advance or during the live session. The life science community’s enthusiasm for the event highlighted the passion and commitment among companies large and small for helping patients affected with rare diseases with new insights, new diagnosis, and new therapies. In case you missed the webinar, it is now available on demand by the following link below: ON-DEMAND VIDEO LINK: http://tinyurl.com/q9698bp Panelists: Philip Reilly MD, JD Venture Partner Third Rock Ventures Alexandra Glucksmann, PhD Chief Operating Officer, Editas Medicine Phil Vickers, PhD Global Head of Research and Development, Shire Gerald Cox, MD, PhD Vice President of Clinical Development, Genzyme, a Sanofi company Richard Soll, PhD SVP and Head of International Discovery Service Unit, WuXi AppTec See Panelist Biographies here.